Serum Levels of Substance P and Response to Antidepressant Pharmacotherapy

Substance P (SP) is possibly involved in the etiopathology of affective disorders. Here we investigated the relationship of SP serum levels and response to antidepressant drug therapy. SP serum levels were determined before and during a 9-week drug trial in 40 depressed patients treated with paroxetine in combination with either lamotrigine (n = 20) or placebo (n = 20). Responders (n = 18) and non-responders (n = 22) significantly differed in SP serum levels: responders started with higher SP levels that decreased during drug therapy, whereas non-responders had lower SP levels that increased at the beginning. There were no differences between patients with adjunct lamotrigine or placebo. These preliminary data indicate that SP serum levels might be related to response to antidepressant drug therapy. Further studies have to substantiate this finding.

References

• 1 Bondy B, Baghai C, Minov C, Schüle C, Schwarz M J, Zwanzger P, Rupprecht R, Möller H J. Substance P serum levels are increased in major depression: preliminary results.  Biol Psychiatr. 2003;  53 538-542
• 2 Herpfer I, Lieb K. Substance P and substance P receptor antagonists in the pathogenesis and treatment of affective disorders.  World J Biol Psychiatr. 2003;  4 56-63
• 3 Kramer M S, Cutler N, Feighner J, Shrivastava R, Carman J, Sramek J J, Reines S A, Liu G, Snavely D, Wyatt-Knowles E, Hale J J, Mills S G, MacCoss M, Swain C J, Harrison T, Hill R G, Hefti F, Scolnick E M, Cascieri M A, Chicchi G G, Sadowski S, Williams A R, Hewson L, Smith D, Rupniak N M. Distinct mechanism for antidepressant activity by blockade of central substance P receptors.  Science. 1998;  281 1640-1645
• 4 Lieb K, Ahlvers K, Dancker K, Strohbusch S, Reincke M, Feige B, Berger M, Riemann D, Voderholzer U. Effects of the neuropeptide substance P on sleep, mood, and neuroendocrine measures in healthy young men.  Neuropsychopharmacology. 2002;  27 1041-1049
• 5 Martensson B, Nyberg S, Toresson G, Brodin E, Bertilsson L. Fluoxetine treatment of depression. Clinical effects, drug concentrations and monoamine metabolites and N-terminally extended substance P in cerebrospinal fluid.  Acta Psychiatr Scand. 1989;  79 586-596
• 6 Normann C, Hummel B, Scharer L O, Horn M, Grunze H, Walden J. Lamotrigine as adjunct to paroxetine in acute depression: a placebo-controlled, double-blind study.  J Clin Psychiatr. 2002;  63 337-344